re: Ann: ANP to Present at BioTech and Health... From the Preso.
ATL1103 Project Status
Phase II clinical trial underway
• Conducted in Europe (UK, France and Spain)
• 13 week dosing study in 24 acromegaly patients
• Open label, baseline comparison of 2 doses
of ATL1103 – 200mg once and twice per week
• Endpoints: safety Endpoints: safety, pK
tolerability and drug activity including the level of tolerability and drug activity including the level of sIGF-I reduction I reduction
• Interim analysis of ATL1103’s effect on sIGF-I levels - results due by end 2013
• Final results anticipated 2’Q’2014
• Next stage of development: Phase III registration
studies in acromegaly post Phase II trial
success
Does that imply that we have 24 patients enrolled.If anybody going to EGM can ask confirmation for that.. Thanks.
Ann: ANP to Present at BioTech and Healthcare Inv, page-2
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $102.2K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 341125 | 4 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |